ArticleFrontiers in oncology2026
A surprising complete radiographic response to palbociclib plus endocrine therapy in an HR-positive, HER2-low lung, pleural, and lymph node metastatic breast cancer patient: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hormone receptor-positive, human epidermal growth factor receptor 2-low (HER2-low) metastatic breast cancer (MBC) constitutes the predominant subtype of advanced breast cancer, with most patients eventually developing resistance to endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). This case report describes a 64-year-old woman with hormone receptor (HR)-positive, HER2-low MBC involving lung, pleural, and lymph node metastases who achieved a remarkable and sustained radiographic complete response (rCR) to palbociclib plus fulvestrant, followed by letrozole after fulvestrant injection intolerance. The patient exhibited near-complete regression of metastatic lesions within 18 months and maintained remission for over 6 years, far exceeding the typical median progression-free survival observed in clinical trials. The prolonged remission observed underscores the existence of biologically distinct tumor subsets with exceptional sensitivity to CDK4/6 inhibition, warranting investigation into underlying molecular mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.